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The Phase I/II Clinical Trials Committee of the Cancer Research
Campaign (CRC) was established in 1980 with the remit of expe-
diting the early clinical evaluation of novel cancer therapeutics. In
order to meet this objective, resources and facilities for the synthesis
and formulation of new agents were made available, and through the
Committee a network of phase I and phase II clinical investigators
was established. In addition, it was recognized that safe, yet rapid,
preclinical toxicology protocols would also be required if
compounds were to progress efficiently into clinical trials. In
designing the preclinical toxicology protocols, note was taken of a
number of retrospective reviews which indicated that one-tenth of
the mouse LD10 (the dose lethal to 10% of mice treated), when doses
are expressed on the basis of surface area (i.e. mg m–2), represents a
safe phase I trial starting dose (Freireich et al, 1966; Homan, 1972;
Goldsmith et al, 1975; Penta et al, 1979; Rozencweig et al, 1981).
More recent experience has largely confirmed the safety of selecting
starting doses for phase I trials on the basis of the mouse toxicology
data (Grieshaber and Marsoni, 1986; Penta et al, 1992; Arbuck et al,
1996). In practise, however, in many countries a non-rodent species,
usually the dog, is still routinely used in preclinical toxicology
studies with cancer therapeutics.
The preclinical toxicology protocols developed by the CRC, in
conjunction with the European Organisation for Research and
Treatment of Cancer (EORTC), took into account the accumu-
lating data on the reliability of the mouse as a predictor of safe
phase I clinical trial starting doses, and deliberately restricted
studies to rodent-only investigations (Joint Steering Committee of
the EORTC and CRC, 1990). In brief, these protocols included
determination of the MTD/LD10 (maximum tolerated dose/dose
lethal to 10% of treated animals) in mice following intraperitoneal
(i.p.), intravenous (i.v.) and, where appropriate, oral (p.o.) admin-
istration. Haematology, histopathology and bone marrow cytology
were performed for up to 28 days after a single dose of the agent at
a dose close to the MTD/LD10, and after repeated dosing, usually
daily for 5 days every week for 4 weeks. Lastly, the haematology,
histopathology and bone marrow cytology studies were repeated
in rats treated daily for 5 days every week for 4 weeks with one-
tenth of the mouse LD10, doses again being expressed as mg m–2.
The latter experiment was performed to check the safety of the
proposed phase I trial starting dose in a second species, in an anal-
ogous manner to the use of the dog (Grieshaber and Marsoni,
1986). The protocols required that studies should be performed
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according to standards of Good Laboratory Practice (GLP), and
used only male animals unless the drug was intended for human
use in females or if there were known sex differences, in which
case the most sensitive sex was used.
Recently, in the light of extensive experience within the CRC
and EORTC, these rodent-only protocols have been revised
(Burtles et al, 1995). Specifically, the protocols now focus on the
use of only clinically relevant schedules, doses (MTD and below)
and routes of administration (i.v. or p.o.). The emphasis in these
revised protocols is on compound-specific toxicology, in order to
both increase the clinical relevance of the results obtained and
reduce the number of animals required. In addition, studies in rats
now repeat directly those in mice to address the need for studies in
two species and which, if either, of the two rodent species is more
predictive of the subsequent human experience.
As of January 1998, the CRC had taken 44 novel cancer thera-
peutics, in which a small molecule drug forms all or part of the
therapy, into phase I trial, i.e. this figure excludes antibody-alone
and gene-based therapeutics. Of these 44 therapies, three were
multi-component, i.e. CMDA or ZD2767 CPG2-A5B7 antibody-
directed enzyme prodrug therapies (ADEPT) and PSC833-
etoposide treatment (multidrug resistance modulation); five were
anti-endocrine agents (4-hydroxyandrostenedione, abiraterone
acetate (CB7630), idoxifene, pyridoglutethimide, zindoxifene);
and for seven agents the phase I trial starting dose was derived
from prior human experience in non-CRC studies (amsalog,
4-hydroxyanisole, eicosapentaenoic acid, D-limonene) or canine
data (AG2034, CT2584, phyllanthoside). Four of the remaining
29 therapies are still under phase I investigation (AMD473,
DMXAA, PK2 and SPAG), leaving 25 agents for which compar-
isons of preclinical rodent toxicology and clinical phase I trial
results can be performed (Table 1).
The primary aim of the current study was to assess retrospec-
tively the safety of using rodent-only toxicology in selecting phase
I trial starting doses. In addition, this study has allowed:
1. A comparison of the quantitative toxicity of novel agents in
mice and humans; i.e. a comparison of the MTD/LD10 in mice
and the MTD or MAD (maximum administered dose) in
patients.
2. An analysis of the qualitative toxicology of compounds in
mice and in humans; specifically, the ability of murine studies
to predict dose-limiting and other human toxicities.
3. An evaluation of the utility of results from early clinical trials
in rapidly optimising schedules for phase II (therapeutic)
evaluation.
MATERIALS AND METHODS
The 25 drugs included in the current analysis are listed in Table 1.
Table 1 also summarizes the properties of the compounds, the
general class to which each compound belongs and references to
the reports describing the phase I clinical trials. The clinical
studies were all approved by, and performed under the auspices of,
the CRC Phase I/II Clinical Trials Committee. In addition, each
trial was approved by the relevant local ethics committee (institu-
tional review board).
Preclinical toxicology studies were performed according to the
protocols previously published (Joint Steering Committee of the
EORTC and CRC, 1990; Burtles et al, 1995), and the full reports
are held on file at the Drug Development Office, CRC, London,
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UK. Experiments were conducted according to local animal
welfare regulations and were covered by a UK Home Office
project licence.
RESULTS
Preclinical toxicology studies
The quantitative preclinical murine toxicology data on the 25
compounds studied are given in Table 2. The route and schedule of
administration were those used in initial clinical studies with only
three exceptions: etoposide phosphate and C6G mustard – where
the clinical route was i.v. and not i.p.; and DACA – where the clin-
ical schedule was daily ´3 and not daily ´5. With the exception
of four drugs (BZQ, mitozolomide, JM216, C6G mustard), the
preclinical toxicology studies were performed according to GLP.
Table 2 also lists the murine MTD/LD10 data, the phase I trial
starting doses and the ratios of the phase I trial starting dose to
the mouse MTD/LD10. In one case, temozolomide, a murine
MTD/LD10, could not be defined because of the limited solubility
of the drug in the i.v. formulation (20% v/v dimethyl sulphoxide
(DMSO) in saline). In all other cases, the MTD/LD10 was defined,
with a very broad range of potencies being observed (0.037–
791 mg kg–1 day–1). Excluding temozolomide, the median (range)
ratio of the phase I trial starting dose to the mouse MTD/LD10 was
0.1 (0.01–0.83), and for 17/24 drugs the starting dose was within
the range 5–15% of the mouse MTD/LD10. For the other seven
drugs there was a greater than 50% deviation from one-tenth of the
mouse MTD/LD10 as the phase I starting dose. The reasons for
these deviations were as follows: clomesone (starting dose:
MTD/LD10 ratio = 0.01), due to a transcriptional error in the clinical
protocol; mitozolomide (0.04), because of the clinical toxicities of
other chloroethylating agents; etoposide phosphate (0.83), due to
prior experience with etoposide; 1069C85 (0.02), and elactocin
(0.01), because of marked toxicity in rats following repeated
administration at one-tenth of the mouse MTD/LD10 (see below);
FAA (0.49), following prior experience with LM985; and trime-
lamol (0.04), due to prior experience with methylmelamines.
The qualitative murine toxicology data for the 25 drugs studied are
summarized in Table 3. Three general categories of toxicology were
recorded: clinical, macroscopic tissue pathology/histopathology and
haematology/chemical pathology. In the case of chemical pathology,
studies were not performed with all the drugs investigated as the
requirement for such tests has only recently been introduced (Burtles
et al, 1995). Furthermore, in describing clinical effects, non-specific
signs such as piloerection and hypokinesia have not been reported. In
addition to listing the toxicities observed with each drug, Table 3 also
indicates the dose level at which the toxicity was observed. Although
in the majority of cases the effects were observed at or below the
i.v./p.o./i.p. MTD/LD10, toxicities were in some cases only observed
at higher dose levels or following repeated administration.
For 13 compounds, a repeat-dose i.p. toxicity study was
performed in rats with five daily doses of one-tenth the mouse
MTD/LD10 being given every week for 4 weeks, i.e. 20 doses in
total. As previously described (Joint Steering Committee of the
EORTC and CRC, 1990), these studies were performed to confirm
the safety of the proposed phase I trial starting dose in a second
species. The drugs studied in rats were CB10-277, clomesone,
temozolomide, didox, MZPES, CI941, etoposide phosphate,
1069C85, amphethinile, elactocin, LM975, SDZ 62-434 and
trimelamol. In the case of temozolomide, one-tenth of the MAD
and not MTD was used, as the latter could not be defined in mice
due to the limited solubility of the drug in the i.v./i.p. vehicle (20%
v/v DMSO in saline). With two exceptions, the only effects seen in
Table 2 Quantitative preclinical murine toxicology of the compounds investigated
Compound Route Sex Schedule GLP MTD/LD10 Mouse MTD/LD10 Phase I start dose Phase I start dose:
(mg kg–1 d–1) (mg m–2 d–1) (mg m–2 d–1) Mouse MTD/LD10 ratio
BZQ i.v. M/F single N 1.1 3.3 0.25 0.08
CB10-277 i.v. M single Y 265 795 80 0.10
Clomesone i.v. M single Y 97 291 4 0.01
MDMS i.v. M single Y 47 141 14 0.10
Mitozolomide i.v. M/F single N 64 192 8 0.04
Temozolomide i.v. M single Y > 140 > 420 50 < 0.12
JM 216 oral F single N 200 600 60 0.10
AG337 i.v. M/F single Y 272 816 75 0.09
Didox i.v. M single Y 791 2373 192 0.08
MZPES i.v. M single Y 18 54 5.4 0.10
CI 941 i.v. M single Y 20 60 5 0.08
DACA i.v. M d ´ 5 Y 30 ´ 5 90 ´ 59   ´ 3 0.10
Etoposide phosphate i.p. M d ´ 5 Y 10 ´ 5 30 ´ 5 25 ´ 5 0.83
1069-C85 oral M single Y 47 141 2.8 0.02
Amphethinile i.v. M single Y 137 411 40 0.10
RSU 1069 i.v. M single Y 150 450 35 0.08
Bryostatin i.v. M single Y 0.037 0.11 0.005 0.05
C6G mustard i.p. M single N 15 45 5 0.11
PK-1 i.v. M single Y 45 135 20 0.15
Elactocin i.v. M single Y 3.6 11 0.1 0.01
FAA i.v. M/F single Y 343 1029 500 0.49
LM985 i.v. M single Y 31 93 10 0.11
Penclomedine i.v. M d ´ 5 Y 80 ´ 5 240 ´ 5 22.5 ´ 5 0.09
SDZ 62-434 i.v. M single Y 15 45 4.5 0.10
Trimelamol i.v. M single Y 206 618 25 0.04
GLP, good laboratory practice. Note: mg/kg doses in mice were converted to mg m–2 doses using a conversion factor of 3.Rodent-only toxicology for early clinical trials 763
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rats following repeated dosing were minor reversible haemato-
logical changes (7/13), decreases in the rate of body weight gain
(4/13) and testicular effects (2/13). However, for two compounds,
1069C85 and elactocin, there was significant toxicity following
repeated administration to rats. With 1069C85 there was signifi-
cant necrosis of the gastrointestinal tract and atrophy of lymphoid
tissues at one-tenth the mouse MTD/LD10, and with elactocin
neither one-tenth nor one-hundreth of the mouse MTD/LD10 were
tolerated by rats on repeated dosing. On the basis of these rat data,
the phase I trial starting doses of 1069C85 and elactocin were
reduced to less than the one-tenth mouse MTD/LD10 (Table 2).
Initial phase I trial results
The quantitative details of the phase I trials initially performed
with the 25 drugs are presented in Table 4. The median number of
patients in the trials was 34, ranging from seven (RSU1069) to 64
(MZPES), and the median number of dose levels was eight,
ranging from three (RSU1069) to 19 (clomesone). The dose esca-
lation schema used in the phase I trials, which included arithmetic
and ‘modified Fibonacci’ approaches, are given in the references
cited in the Table 1. Table 4 also lists the human MAD, and for
20/25 drugs dose-limiting toxicity (DLT) was observed at or below
the MAD. For the remaining five drugs, the initial clinical study
was stopped before DLT was observed, either because administra-
tion was changed to an alternative route (temozolomide) or
schedule (JM216, AG337), or because drug supplies were
exhausted (C6G mustard and SDZ 62-434). Results of the subse-
quent clinical studies with temozolomide, JM216 and AG337 are
discussed below.
Table 4 also compares the human MAD and the mouse
MTD/LD10, and gives the ratios of these two values. With the three
exceptions indicated previously, i.e. DACA, etoposide phosphate
and C6G mustard, the murine and clinical data are directly compa-
rable in terms of route and schedule of administration. A compar-
ison of the human MAD and the murine MTD/LD10 values is
shown graphically in Figure 1, and for the 20 drugs where DLT
was observed at the human MAD, the median ratio of the human
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Figure 1 Relationship between the mouse maximum tolerated dose/dose
lethal to 10% of animals (MTD/LD10) and the human maximum administered
dose (MAD) for 24 anti-tumour agents. Each symbol is an individual drug;
temozolomide is omitted as the mouse MTD/LD10 was not defined. The open
symbols are the drugs for which dose-limiting toxicity (DLT) was observed
and the closed symbols are those where DLT was not observed in the initial
clinical studies. The solid line is the line of identify (human MAD: mouse
MTD/LD10 = 1) and the broken line is the line for a phase I trial starting dose
of one-tenth the mouse MTD/LD10764 DR Newell et al
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MAD to the mouse MTD/LD10 was 2.6, with a range of 0.2–16.
For the same 20 drugs, the median ratio of the phase I trial starting
dose to the eventual MAD was 35, ranging from 2.3 to 160, i.e.
DLT was not observed at the starting dose for any these drugs. By
definition, for the five drugs where DLT was not observed in the
phase I trial, the phase I trial starting dose was also safe.
Furthermore, for the five drugs (clomesone, mitozolomide,
1069C85, elactocin and trimelamol), where for various reasons
(see above) the phase I trial starting doses were less than the one-
tenth the mouse MTD/LD10, DLT would not have been observed
Table 4 Phase I trial details, maximum doses administered and ratios of human MAD to murine MTD/LD10 doses
Compound Schedule Starting dose No. patients No. dose levels Human MAD Mouse MTD/LD10 Human MAD:
(mg sq.m–1 d–1) (mg m–2 d–1) (mg m–2 d–) Mouse MTD/LD10
BZQ iv bolus 0.25 34 15 33 3.3 10.0
CB10-277 Short i.v. infusion 80 36 11 6000 795 7.5
Clomesone 30 min i.v. infusion 4 63 19 639 291 2.2
MDMS iv bolus 14 39 9 225 141 1.6
Mitozolomide 1-h i.v. infusion 8 37 9 153 192 0.8
Temozolomide 1-h i.v. infusion 50 16 4 200 > 420 > 0.48
JM 216 Single oral dose 60 31 7 700 600 1.2
AG337 24-h i.v. infusion 75 13 6 1350 816 1.7
Didox Bolus – 30-min iv infusion 192 34 14 10000 2373 4.2
MZPES 1-h iv infusion 5.4 64 18 460 54 8.5
CI 941 iv bolus 5 44 12 55 60 0.9
DACA 3-h i.v. infusion, d ´ 39   ´ 3 41 11 800 ´ 3 90 ´ 5 8.9
Etoposide phosphate 30–60 min i.v. infusion, d ´ 5 25 ´ 5 31 5 110 ´ 5 30 ´ 5 3.7
1069-C85 Single oral dose 2.8 39 8 200 141 1.4
Amphethinile Bolus – short i.v. infusion 40 15 5 1200 411 2.9
RSU 1069 15-min i.v. infusion 35 7 3 80 450 0.2
Bryostatin 1-h i.v. infusion 0.005 19 6 0.065 0.11 0.6
C6G mustard i.v. bolus 5 35 8 80 45 1.8
PK-1 1-h i.v. infusion 20 36 8 320 135 2.4
Elactocin 1-h i.v. infusion 0.1 10 6 4 11 0.4
FAA 1-h i.v. infusion 500 27 8 6400 1029 6.2
LM985 1-h i.v. infusion 10 26 14 1500 93 16.1
Penclomedine 1-h i.v. infusion, d ´ 5 22.5 ´ 5 16 5 340 ´ 5 240 ´ 5 1.4
SDZ 62-434 i.v. bolus 4.5 31 12 240 45 5.3
Trimelamol i.v. bolus 25 49 14 2400 618 3.9
Table 5 Qualitative human toxicology and predictive performance of preclinical murine studies
Compound Dose-limiting toxicity Predicted Other toxicities observed (not dose-limiting) Predicted
BZQ N&V NE Diarrhoea, alopecia, haematological N, NR, NR
CB10-277 N&V NE Flushing, diarrhoea, rash NE, Y, NE
Clomesone Haematological Y Cardiac, N&V, hepatic N, NE, N
MDMS Haematological Y N&V, alopecia, phlebitis NE, N, N
Mitozolomide Haematological Y N&V NE
Temozolomide Not reached Haematological Y
JM 216 Not reached N&V, diarrhoea, haematological, mucositis NE, Y, Y, Y
AG337 Not reached N&V, hepatic, phlebitis NE, N, Y
Didox Hepatic N Renal, N&V, hypotension, diarrhoea N, NE, NE, Y
MZPES N&V, neurotoxicity NE, Y Haematological Y
CI 941 Haematological Y N&V, mucositis, diarrhoea, alopecia, skin NE, Y, Y, N, Y
DACA Arm pain during infusion NE Flushing, N&V, haematological, chest pain NE, NE, Y, NE
Etoposide phosphate Haematological Y N&V, diarrhoea, hypersensitivity, mucositis, phlebitis, malaise, alopecia. NE, Y, NE, Y, NE, NE, N
1069-C85 Neurotoxicity Y Haematological, diarrhoea, N&V, alopecia Y, Y, NE, Y
Amphethinile Not defined Neurotoxicity, N&V, alopecia, aesthenia, diarrhoea, haematological, pain Y, NE, Y, NE, Y, Y, NE
RSU 1069 N&V NE
Bryostatin Myalgia NE Lethargy, fever/rigors, hypotension, headache, haematological NE, NE, NE, NE, Y
C6G mustard Not reached N&V, mucositis NE, N
PK-1 Haematological, mucositis Y, Y N&V, alopecia, lethargy, hepatic, neurotoxicity NE, N, NE, Y, Y
Elactocin Aesthenia, N&V NE, NE Hepatic N
FAA Flushing NE N&V, myalgia NE, NE
LM985 Hypotension NE N&V, neurotoxicity NE, Y
Penclomedine Neurotoxicity Y N&V NE
SDZ 62-434 Not reached N&V, diarrhoea, headaches, neurotoxicity NE, N, NE, N
Trimelamol Haematological Y N&V, diarrhoea, aesthenia NE, N, NE
N&V, nausea and vomiting; NE, not evaluable in murine studies; NR, not reported in murine experiments.Rodent-only toxicology for early clinical trials 765
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even if one-tenth the mouse MTD/LD10 had been used. This latter
point is illustrated by the data points all being above the broken
line in Figure 1.
The qualitative human toxicology data for the 25 compounds
studied are presented in Table 5. Toxicities are distinguished as
being either dose-limiting or not on the basis of the phase I trial
reports (see Table 1). By comparing the data in Table 5 with those
in Table 3, the ability of the preclinical murine studies to predict
each human toxicity was determined. In comparing the human and
murine data, it was recognized that a number of the human toxici-
ties were either not evaluable or not evaluated in the preclinical
experiments. The non-evaluable toxicities were nausea and
vomiting, malaise/asthenia, flushing, fever/rigors, hypotension,
headache, chest pain, hypersensitivity, rash, pain and myalgia. For
the 20 drugs where DLT was observed, 22 toxic events were
described as being dose-limiting. In the case of amphethinile,
although DLT was reached, the exact nature of the DLT was not
defined. The most common DLTs were haematological (7/22),
nausea and vomiting (5/22) and neurotoxicity (3/22), the
remaining DLTs only being reported on one occasion each. Of the
human DLTs that were evaluated in the murine studies (12/22), 11
were correctly predicted, i.e. haematological seven, neurological
three and mucositis one. Didox was the only drug where the
human dose-limiting end organ, the liver, was studied in the
preclinical experiments but toxicity was not observed. In total
there were 78 other or non-DLTs reported, the most common being
nausea and vomiting (18/78), diarrhoea (10/78), haematological
(8/78), alopecia (7/78), malaise/asthenia (5/78), mucositis (4/78),
hepatic (4/78) and neurological (4/78). Other toxicities occurred
with an incidence of < 4 in 78 (i.e. < 5%). For the more common
non-DLTs that were evaluated in the murine studies, the ability of
the preclinical experiments to predict the human observations was
as follows: diarrhoea 7/10, haematological 7/7, alopecia 2/6,
mucositis 3/4, neurological 3/4 and hepatic 1/4.
Subsequent phase I trial results
On the basis of the initial phase I trial results presented in Tables 4
and 5, 11 compounds were subject to a total of 13 further dose
escalation studies in an attempt to optimize the dose, route and/or
schedule of administration prior to therapeutic evaluation. As
shown in Table 6, these additional studies involved a median of
32 patients per trial (range 6–42) and a median of 5 (range 3–12)
dose levels. Importantly, the median ratio of the starting to the
maximum dose administered was only 2.8 (range 1.6–56), i.e. a
much smaller ratio than in the initial clinical trials (Table 4).
DISCUSSION
The primary aim of the studies described in this paper was to
evaluate the safety of initiating phase I trials with novel cancer
therapeutics on the basis of rodent-only toxicology studies.
Specifically, for all 24 drugs for which a mouse MTD/LD10 was
defined, one-tenth of this dose was, or would have been, safe in
humans. With two compounds DLT was observed in patients at
doses clearly less that the mouse MTD/LD10, i.e. RSU1069 (DLT –
nausea and vomiting) and elactocin (DLTs – asthenia/malaise and
nausea/vomiting). However, for both drugs the DLTs were not
evaluable in mice. Although for seven drugs the phase I trial
starting dose was not in fact one-tenth the mouse MTD/LD10, or
close to it, had one-tenth the mouse MTD/LD10 been used DLT
would not have been encountered. Lastly, in the case of three
compounds (AG337, flavone acetic acid and penclomidine) dog
toxicology data were available at the time phase I trials were initi-
ated; however, in all three cases the mouse was the most sensitive
species and hence the phase I trial starting dose was based on the
murine data.
The results reported here are in agreement with earlier retrospec-
tive reviews of the relationships between preclinical and clinical
toxicology data (Freireich et al, 1966; Homan, 1972; Goldsmith et
al, 1975; Penta et al, 1979; Rozencweig et al, 1981) as well as, in
the main, more recent studies (Grieshaber and Marsoni, 1986;
Penta et al, 1992; Arbuck et al, 1996). In these latter more recent
reviews, which in some cases included certain of the drugs
described here, a small number of drugs were identified where initi-
ation of phase I trials at one-tenth of the mouse MTD/LD10 would
have exceeded the human MTD. The three most clear-cut instances
were fludarabine (Grieshaber and Marsoni, 1986), tallimustine
(Dent and Eisenhauer, 1996) and LY231514 (Dent and Eisenhauer,
1996). Both fludarabine and LY231514 are antimetabolites, and
interspecies differences in the whole animal and cellular pharma-
cology of this class of drugs is well recognized. Of the 25 drugs
Table 6 Details of subsequent phase I trials performed using results from initial studies (see Tables 4 and 5)
Compound Schedules Starting dose No. patients No. dose levels MAD DLT
mg m–2 d–1 mg m–2 d–1
CB10-277 24-h i.v. infusion 4700 22 5 15000 Myelosuppression
Temozolomide Oral, d ´ 1 200 35 12 1200 Myelosuppression
Temozolomide Oral, d ´ 5 150 ´ 5 42 4 240 ´ 5 Myelosuppression
JM216 Oral, d ´ 5 30 ´ 5 32 5 140 ´ 5 Myelosuppression
AG337 120-h i.v. infusion 96 ´ 5 32 9 1040 ´ 5 Myelosuppression
Didox 36-h i.v. infusion 2500 ´ 3 12 4 7000 ´ 3 Hepatic
MZPES 24-h i.v. infusion 460 6 3 800 N&V, neurotoxicity
DACA 3-h i.v. infusion 18 32 9 1000 Arm pain during infusion
Bryostatin Various weekly 0.025 35 4 0.05 Myalgia
Bryostatin 24-h i.v. infusion 0.025 19 3 0.05 Myalgia
Elactocin Various 1.5 23 5 4 ´ 5 Aesthenia, N&V
FAA 3- and 6-h i.v. infusion 4800 27 5 10000 Hypotension, diarrhoea
Trimelamol i.v., d ´ 3 500 ´ 3 33 6 1000 ´ 3 Myelosuppression
N&V, nausea and vomiting.766 DR Newell et al
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studied by the CRC, three were antimetabolites (AG337, didox and
MZPES) and for all three agents the murine toxicology safely iden-
tified a safe phase I trial starting dose. However, it should be noted
that these three drugs are direct-acting antimetabolites, i.e. unlike
classical antifolates and base/nucleoside analogues, they are not
subject to intracellular metabolic activation. As such, the three
antimetabolites studied here may not be representative of the drug
class as a whole. Particular care needs to be taken in selecting phase
I trial starting doses with antimetabolites, especially when the
compound is known to undergo metabolic activation.
In general, the use of two species in preclinical toxicology
studies is recommended in order to identify and compensate for
marked interspecies differences. Most authorities require studies in
one rodent and one non-rodent species, the non-rodent species
usually being the dog. In reviewing data on 27 phase I trials with 17
new cytotoxic drugs, Dent and Eisenhauer (1996) concluded that
dog toxicology data had appropriately influenced the choice of the
phase I trial starting dose on three of the six occasions it was used
(topotecan, LY231514, tallimustine). However, in reviewing data
collated by Verweij (1996), Arbuck noted that the rat may also be
able to safely identify a phase I trial starting dose, even when there
were marked species differences in toxicology (Arbuck, 1996). In
the current study, rat toxicology studies were only performed on a
sub-set of 13 compounds, and then solely to check the safety of the
proposed phase I trial starting dose, i.e. one-tenth the mouse
MTD/LD10, when given by repeated administration. Hence a
comparison of the relative abilities of mouse and rat toxicology
studies to predict quantitative and qualitative human toxicology
data cannot be made on the basis of the results presented here.
Recent modifications to the CRC/EORTC protocols will allow
a direct comparison of mouse, rat and human toxicology data
(Burtles et al, 1995), and results are currently being accumulated.
In addition to the primary aim of determining the safety of one-
tenth of the mouse MTD/LD10 as a phase I trial starting dose, this
study has allowed a comparison of the quantitative and qualitative
murine and human toxicologies for a range of drugs with widely
varying structures, mechanisms of action and potencies. A compar-
ison of the human MAD and the mouse MTD/LD10, for drugs
where clinical DLT was achieved, revealed a median ratio of 2.6
(range 0.2–16), a value and a range similar to those reported previ-
ously (Freireich et al, 1966; Homan, 1972; Goldsmith et al, 1975;
Penta et al, 1979; Rozencweig et al, 1981; Grieshaber and Marsoni,
1986; Penta et al, 1992; Arbuck et al, 1996; Dent and Eisenhauer,
1996). With respect to the ability of the mouse to predict the quali-
tative nature of toxicities subsequently observed in humans, the
data are again in agreement with earlier comparisons. Thus, haema-
tological, neurological and antiproliferative-gastrointestinal human
toxicities were predicted in most cases by the murine studies.
Whilst it is recognized that mice, and to a lesser extent rats, do not
allow investigations of the extent and sophistication possible in
larger animals, the experience of the CRC is that this does not
compromise patient safety, and that toxicities which more
frequently become dose-limiting in human trials are detected in
murine studies. In addition to systematically evaluating the rat in
preclinical toxicology studies, recent revisions to the CRC/EORTC
protocols (Burtles et al, 1995) include the routine use of chemical
pathology studies, and these may help to identify less common side
effects, e.g. renal, hepatic and cardiac toxicities, more reliably.
As noted by Dent and Eisenhauer (1996), phase I trials can be
subdivided into those representing the first human experience with
the drug, and those based on prior clinical data. In the current
analysis, a similar distinction was made and the results obtained
indicate that, once human data are available, subsequent clinical
trials are in most cases conducted over a much smaller dose range,
a median of 2.8 for the subsequent trials in Table 6 versus 35 for
the initial trials listed in Table 4. Although clinical responses in
phase I trials are rare (Estey et al, 1986; Decoster et al, 1990; Penta
et al, 1992; Arbuck, 1996), they are more frequent at doses close
to the MTD/recommended phase II dose (Penta et al, 1992), and
hence it is important to minimize the number of patients treated in
phase I trials at lower dose levels. From the data in Table 6, it is
apparent that one approach to reducing the number of patients
treated at doses that are unlikely to be effective is to rapidly obtain
initial clinical data and then optimize the human dose, route and
schedule of administration.
In the studies described in this paper, a range of approaches to
dose escalation were used and, for the initial clinical studies (Table
4), the number of patients entered and dose levels required varied
widely (median (range)), i.e. 34 (7–64) and 8 (3–19) respectively.
Although it was not the aim of the current study to analyse the rela-
tive merits of the different dose escalation schemes used, the issues
of dose escalation and phase I trial starting dose identification are
intimately linked. Whilst the use of a ‘homeopathic’ phase I trial
starting dose would invariably be safe, too conservative a starting
dose can result in over lengthy dose escalation, time delays in
starting therapeutic trials, the unnecessary use of clinical resources
and large numbers of patients being treated at doses that are not
even potentially therapeutic (Collins et al, 1986; Collins et al,
1990; Penta et al, 1992; Ratain et al, 1993; Simon et al, 1997). On
the basis of the data presented here, one-tenth of the mouse
MTD/LD10 as a phase I trial starting dose appears to be a satisfac-
tory compromise between a dose that is safe, but too low, and one
that is more likely to be therapeutic, but also toxic. Once the phase
I trial has been safely initiated, the challenge of rapidly identifying
a dose for therapeutic evaluation should focus on the use of
innovative dose escalation approaches including the application of
all available preclinical data, pharmacologically guided dosing,
model-based study designs and the use of pharmacodynamic trial-
end points (Collins et al, 1986, 1990; EORTC Pharmacokinetics
and Metabolism Group, 1987; O’Quigley and Chevret, 1991; Mick
and Ratain, 1993; Ratain et al, 1993; Arbuck, 1996; Dent and
Eisenhauer, 1996; Simon et al, 1997). In order to expedite such
innovative designs it is essential that pharmacokinetic and pharma-
codynamic investigations are included in preclinical toxicology
studies wherever possible.
In considering the results of the preclinical and clinical studies
described in this paper, and their implications for the identification
of new cancer treatments, it is important to recognize the stages of
clinical drug development these preclinical studies are intended to
facilitate. The aim of the original and revised CRC/EORTC
toxicology protocols (Joint Steering Group of the EORTC and
CRC, 1990; Burtles et al, 1995) was to allow the rapid yet safe
introduction of new cancer drugs into phase I trials and, provided
acceptable clinical toxicology and pharmacology are observed,
phase II therapy studies. The CRC/EORTC toxicology protocols
are therefore intended to facilitate the equivalent of a United States
Food and Drug Administration Investigational New Drug applica-
tion (FDA-IND). In discussing regulatory considerations relevant
to the preclinical development of anticancer drugs, DeGeorge and
colleagues have recently emphasized the important distinction
between studies required for an FDA-IND and those required to
support a New Drug Application (NDA) (DeGeorge et al, 1998). InRodent-only toxicology for early clinical trials 767
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the design of toxicology studies to support an NDA, these authors
recognized the need to take into account the proposed therapeutic
indication, the outcome of early clinical development, the nature of
toxicities seen in animals and in humans, and the projected duration
of clinical treatment. Whilst it is envisaged that the preclinical
toxicology protocols used by the CRC/EORTC should ultimately
facilitate NDA-type clinical trials, these protocols are not seen as a
substitute for the more detailed compound-specific toxicology
studies that may be required for product registration.
Although, of necessity, the study described in this paper consti-
tutes a retrospective analysis, given the need to accrue both
preclinical and clinical data, it represents the prospective evalua-
tion of rodent-only preclinical toxicity studies. As such, the orig-
inal hypothesis that rodent-only toxicity studies can be used to
identify safe phase I trial starting doses has been tested and
proven, for the 25 drugs studied. Of the 25 drugs investigated the
majority (15) were conventional cytotoxic drugs (i.e. alkylating
agents, antimetabolites, topoisomerase inhibitors or tubulin
binding agents; Table 1), and hence caution must be exercised in
extrapolating from the current results to newer classes of agents
acting by novel mechanisms, e.g. mitogenic signal transduction
inhibitors, anti-angiogenic and antimetastatic agents. However,
clinical experience with these newer classes of drugs is currently
insufficient to allow firm recommendations as to the most relevant
preclinical toxicology models to use, and hence the emphasis
should be on compound-specific protocols in the first instance.
Specifically, in the context of the current study, it is not possible to
comment on the relative merits of rodent and non-rodent species.
In general, with the development of agents designed to exploit
specific tumour-associated molecular lesions, the issue of target-
related versus target-unrelated toxicity is likely to assume greater
importance. In designing preclinical studies to address this issue,
the increasing availability of gene knockout mice may have an
important role to play. For example, toxicities seen in mice lacking
the gene for the drug target must, by definition, be unrelated to the
proposed mechanism of the anti-tumour action of the drug. Studies
with gene knockout animals are likely to be restricted to rodents
for the foreseeable future, and hence are complementary to the
rodent-only approach described here.
In summary, the experience of the CRC in the phase I evaluation
of 25 novel cancer therapeutics has shown that 1/10th the mouse
MTD/LD10 represented a safe Phase I trial starting dose for every
drug. With the exception of nausea and vomiting, which cannot be
evaluated in rodents, the more common human DLTs (haemato-
logical and neurological toxicity) were reliably predicted by the
murine studies. These data do not support the routine use of a
non-rodent species in preclinical toxicology studies prior to initial
clinical trials with anticancer treatments.
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